🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This open-label, randomized, 2-arm, multicenter, phase 3 study has the prim...
Status
Completed
Location
Multiple Locations
Start Date
2012-11-09
Trial ID
NCT01712490
Treatments Being Tested
This study will be held in the clinical oncology department, Helwan Univers...
Status
Completed
Location
Helwan University
Start Date
2023-03-01
Trial ID
NCT07171827
The addition of targeted immunotherapy will be safe and well tolerated and ...
Status
Recruiting
Location
University of Alabama
Start Date
2022-02-01
Trial ID
NCT05253495
Treatments Being Tested
This study is a survey in Japan of Brentuximab Vedotin used to treat childr...
Status
Recruiting
Location
Takeda selected site
Start Date
2022-08-01
Trial ID
NCT05481437
Treatments Being Tested
The purpose of this study is to assess the efficacy of two three-weekly 1.8...
Status
Unknown
Location
Institute of Hematology and Medical Oncology "L. e A. Seràgnoli" at the University of Bologna
Start Date
2013-04
Trial ID
NCT02275598
Treatments Being Tested
The purpose of this study is to test whether BV-AVD is an effective treatme...
Status
Recruiting
Location
University of Miami
Start Date
2024-04-17
Trial ID
NCT06377566
This phase II trial studies how well giving brentuximab vedotin together wi...
Status
Completed
Location
Stanford University Medical Center
Start Date
2011-11
Trial ID
NCT01476410
This phase III trial compares immunotherapy drugs (nivolumab or brentuximab...
Status
Active Not Recruiting
Location
Children's Hospital of Alabama
Start Date
2019-08-29
Trial ID
NCT03907488
This is a phase II study using risk and response-adapted therapy for low, i...
Status
Active Not Recruiting
Location
Lucile Packard Children's Hospital Stanford University
Start Date
2018-12-12
Trial ID
NCT03755804
Brentuximab is an antibody-drug conjugate (ADC), which is the combination o...
Status
Completed
Location
Moffitt Cancer Center
Start Date
2012-03
Trial ID
NCT01534078
Treatments Being Tested